Application of small molecule compound pimavanserin to preparation of medicine for resisting SARS-CoV-2

A small molecule compound, pimavanserin technology, applied in the field of medicine, can solve the problems of limited clinical efficacy and achieve the effect of low cytotoxicity

Active Publication Date: 2021-12-17
THE NAVAL MEDICAL UNIV OF PLA
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although remdesivir has received emergency use authorization from the U.S. Food and Drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of small molecule compound pimavanserin to preparation of medicine for resisting SARS-CoV-2
  • Application of small molecule compound pimavanserin to preparation of medicine for resisting SARS-CoV-2
  • Application of small molecule compound pimavanserin to preparation of medicine for resisting SARS-CoV-2

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] 1. Experimental drugs, reagents and materials

[0022] 1. Compounds: Small molecule drug library (product number: L1300-Z349373) approved by the US FDA for clinical use, containing 2580 small molecule compounds, purchased from Selleck, USA, all dissolved in DMSO at a concentration of 10 μM. Remdesivir, purchased from Selleck, USA, was dissolved in DMSO at a concentration of 10 μM.

[0023] 2. African green monkey kidney cells Vero E6 and human lung adenocarcinoma cells Calu-3 were purchased from the Shanghai Cell Institute of the Chinese Academy of Sciences and preserved by the Department of Biomedical Protection, Department of Naval Medicine, Naval Medical University of the Chinese People's Liberation Army.

[0024] 3. DMEM complete cell culture medium, containing 10% fetal bovine serum, 0.03% glutamine, non-essential amino acids, ampicillin and streptomycin 100U / mL, adjust the pH to 7.4.

[0025] 4. Cell digestion solution, containing 0.25% trypsin, prepared with pho...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of a small molecule compound pimavanserin to preparation of a medicine for resisting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The medicine for resisting the SARS-CoV-2 is a medicine composition which takes the pimavanserin as a unique active ingredient or contains the pimavanserin, and the medicine for resisting the SARS-CoV-2 refers to a medicine for preventing or treating SARS-CoV-2 infection. According to the invention, a susceptible cell line of the SARS-CoV-2, including an African green monkey kidney cell Vero E6 and a human lung adenocarcinoma cell Calu-3, is utilized to detect the anti-SARS-CoV-2 activity of the pimavanserin. Experimental results show that the pimavanserin can effectively inhibit infection of the SARS-CoV-2 on the susceptible cells, is relatively low in cytotoxicity, is expected to be used as a medicine for effectively resisting SARS-CoV-2 infection, and has an application prospect.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of the small molecular compound pimavanserin in the preparation of anti-SARS-CoV-2 drugs. Background technique [0002] Pimavanserin, a small molecule compound, is a highly efficient and selective 5-HT2A inverse agonist approved by the US FDA for clinical use in the treatment of Parkinson's disease-related delirium. There is currently no literature reporting its role in anti-SARS-CoV-2. [0003] The chemical structure of pimavanserin is as follows (CAS No.706782-28-7): [0004] [0005] Severe acute respiratory syndrome coronavirus 2 (Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2), is a new highly infectious and highly pathogenic infectious disease pathogen, which mainly passes through the respiratory tract through droplets, close contact, etc. spread. The disease caused by SARS-CoV-2 infection is called coronavirus disease 2019 (C...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4468A61P31/14
CPCA61K31/4468A61P31/14
Inventor 郑旭彭浩然丁翠玲刘燕江亮亮何燕华赵平戚中田
Owner THE NAVAL MEDICAL UNIV OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap